Business
Alkermes Expands Awards Program With Focus on Advancing Research in Schizophrenia
DUBLIN, April 3, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the next evolution of the ALKERMES PATHWAYS RESEARCH AWARDSSM program, an
About this update from Alkermes Plc
[{"type":"text","content":" DUBLIN, April 3, 2019 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today announced the next evolution of the ALKERMES PATHWAYS RESEARCH AWARDSSM program, an initiative designed to support the next generation of researchers who are working on the front lines to advance understanding and awareness of central nervous system (CNS) disorders. The program will continue to support projects focused on helping those living with substance use disorders (SUDs) and is expanding to include projects dedicated to helping people living with schizophrenia. The current application cycle will run through July 31, 2019. \n\"The Pathways program exemplifies our company's commitment to helping researchers find unique and meaningful ways to impact the people and communities we serve with our medicines,\" said Craig Hopkinson, M.D., Chief Medical Officer and Senior Vice President of Medicines Development and Medical Affairs at Alkermes. \"We are optimistic that expanding the program to include projects supporting schizophrenia will bring additional innovation and advances in research to this scientific and clinical community.\"\nNow open to early-career investigators committed to advancing research in SUDs and/or schizophrenia, the second annual Pathways program grants will provide funding for up to eight research projects with individual grant amounts of up to $100,000 per project. Alkermes has reserved four awards for research focused on SUDs and four awards for research focused on schizophrenia.\n\"The Pathways grant that I received last year allowed me to jumpstart my research project and career in a way that otherwise might not have been possible,\" said Derek Blevins, M.D., Columbia University, New York State Psychiatric Institute and inaugural Alkermes Pathways award grantee. \"Alkermes investing in young scientists like me to bring research projects to fruition really demonstrates the company's commitment to building a better future for people living with debilitating CNS disorders.\"\nTo qualify, early-career investigators must be M.D.s, Ph.D.s or equivalent, who are within five years of their initial academic appointment or are currently post-doctoral fellows, and who are affiliated with a medical or research center within the United States. Full eligibility criteria are available on the program website here. \nAbout Alkermes plc Alkermes plc...